Phenylalanine derivatives of formula (1) are described:
wherein
R is a carboxylic acid or a derivative thereof;
L1 is a linker atom or group;
Het is an optionally substituted heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of alpha4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
Squaric acid Derivatives of formula (1) are described:
1
wherein
R
1
is an integrin binding group;
R
2
is a hydrogen atom or a C
1-6
alkyl group;
L
1
is a covalent bond or a linker atom or group;
n is zero or the integer 1;
Alk
1
is an optionally substituted aliphatic chain;
R
3
is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group:
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune of inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.
The present invention relates to compounds of formula I:
or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.